Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

Experimental Tumor Clinical Trial

Official title:
Chidamide Maintenance Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk Lymphoma : a Prospective, Multi-centric, Single Arm, Open Label Phase II Clinical Trial

Status Not yet recruiting

Clinical Trial Summary

Chidamide Maintenance Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk Lymphoma : a Prospective, Multi-centric, Single Arm, Open Label Phase II Clinical Trial

Clinical Trial Description

Chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide as Maintenance Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk Lymphoma ;

Study Design

Related Conditions & MeSH terms

Experimental Tumor

Clinical Trial Details

NCT number	NCT03611231
Study type	Interventional
Source	Peking University
Contact	Yuqin Song, Dr.
Phone	0086 13683398726???
Email	songyuqin622@163.com
Status	Not yet recruiting
Phase	Phase 2
Start date	September 1, 2018
Completion date	December 30, 2022

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT03617432` - Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients	Phase 2
	Not yet recruiting	`NCT03494634` - Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors	Phase 2